COVID-19 vaccine equity in Africa

被引：11

作者：

Turyasingura, Natasha ^{[1
]}

James, Wilmot G. ^{[2
]}

Vermund, Sten H. ^{[1
]}

机构：

[1] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06510 USA

[2] Columbia Univ, Inst Social & Econ Policy & Res, New York, NY 10027 USA

来源：

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE | 2023年 / 117卷 / 06期

关键词：

Africa; COVID-19; vaccines; health equity; health services accessibility; global health; vulnerable populations;

D O I：

10.1093/trstmh/trac130

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The coronavirus disease 2019 (COVID-19) pandemic has dominated global health discourse since early 2020. By early 2021, the unprecedented speed of vaccine development against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by government, academia and industry contributed biotechnological tools to reduce severe COVID-19 infections, hospitalizations and deaths. However, vaccine distribution has not been equitable. We address one element of this challenge, namely the low COVID-19 vaccination rates in African countries, which lag behind higher-income nations. We evaluate key obstacles to initiatives addressing this inequity and emphasize Africa-based research and development as a sustainable solution to ensuring vaccine equity in Africa.

引用

页码：470 / 472

页数：3

共 10 条

[1]

Adepoju P., LACK ORDERS COULD HA

[2]

African Union Africa Centres for Disease Control, JOINT STAT DOS DON C

[3]

African Union Africa Centres for Disease Control, COVID 19 VACC AFR CD

[4] Medicinal Chemistry Out of Africa [J].

Chibale, Kelly ;

Wicht, Kathryn J. ;

Woodland, John G. .

JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (15) :10513-10516

[5] Addressing the Cold Reality of mRNA Vaccine Stability [J].

Crommelin, Daan J. A. ;

Anchordoquy, Thomas J. ;

Volkin, David B. ;

Jiskoot, Wim ;

Mastrobattista, Enrico .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 110 (03) :997-1001

[6]

Jerving S., LAUNCHES PARTNERSHIP

[7]

Malpani R., DOSE REALITY RICH CO

[8] Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination [J].

Perez-Then, Eddy ;

Lucas, Carolina ;

Monteiro, Valter Silva ;

Miric, Marija ;

Brache, Vivian ;

Cochon, Leila ;

Vogels, Chantal B. F. ;

Malik, Amyn A. ;

De la Cruz, Elena ;

Jorge, Aidelis ;

De los Santos, Margarita ;

Leon, Patricia ;

Breban, Mallery, I ;

Billig, Kendall ;

Yildirim, Inci ;

Pearson, Claire ;

Downing, Randy ;

Gagnon, Emily ;

Muyombwe, Anthony ;

Razeq, Jafar ;

Campbell, Melissa ;

Ko, Albert, I ;

Omer, Saad B. ;

Grubaugh, Nathan D. ;

Vermund, Sten H. ;

Iwasaki, Akiko .

NATURE MEDICINE, 2022, 28 (03) :481-+

[9] Investing in health R&D: where we are, what limits us, and how to make progress in Africa [J].

Simpkin, Victoria ;

Namubiru-Mwaura, Evelyn ;

Clarke, Lorcan ;

Mossialos, Elias .

BMJ GLOBAL HEALTH, 2019, 4 (02)

[10]

UNICEF Supply Division, COVID 19 VACC MARK D

← 1 →